Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Mar 3:6:87-93.
doi: 10.2147/vhrm.s9404.

Valsartan addition to amlodipine is more effective than losartan addition in hypertensive patients inadequately controlled by amlodipine

Roberto Fogari  1 , Amedeo Mugellini, Paola Preti, Annalisa Zoppi, Giuseppe Derosa
Affiliations
Randomized Controlled Trial

Valsartan addition to amlodipine is more effective than losartan addition in hypertensive patients inadequately controlled by amlodipine

Roberto Fogari et al. Vasc Health Risk Manag. .

Abstract

Introduction: This study evaluated the effects on blood pressure (BP) of valsartan 160 mg or losartan 100 mg addition to amlodipine 5 mg in hypertensive patients.

Methods: 221 patients with inadequately controlled BP (DBP >or= 90 mmHg) after 4 weeks of treatment with amlodipine 5 mg were randomized to receive losartan/amlodipine combination therapy or valsartan/amlodipine combination therapy for 4 weeks in a cross-over study design. At the end of the wash-out period and of each treatment period, clinic and ambulatory BP measurements were recorded.

Results: 166 patients completed the study. Both combination treatments induced a greater ambulatory BP reduction than did monotherapy. However, the further mean reductions in BP versus monotherapy were significantly greater with the valsartan/amlodipine combination (SBP/DBP: -7.9 +/- 3.4/-6.5 +/- 2.6 mmHg for 24-hour, -8.0 +/- 3.4/-6.6 +/- 2.7 mmHg for daytime; -7.7 +/- 3.3/-6.4 +/- 2.7 mmHg for nighttime) than with the losartan/amlodipine combination (SBP/DBP: -5.5 +/- 2.8/-4.2 +/- 2.1 mmHg for 24-hour, -5.7 +/- 2.9/-4.4 +/- 2.2 mmHg for daytime; -4.8 +/- 2.8/-3.7 +/- 2.2 mmHg for nighttime; P < 0.01 vs valsartan/amlodipine). The incidence of adverse events with valsartan/amlodipine (8%) and losartan/amlodipine (9%) was lower than that observed with amlodipine monotherapy (17%; P < 0.05 vs combinations).

Conclusion: Valsartan 160 mg plus amlodipine 5 mg produced greater BP reductions than losartan 100 mg plus amlodipine 5 mg.

Keywords: ambulatory blood pressure monitoring; amlodipine; angiotensin receptor blocker; combination therapy; losartan; valsartan.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mean ambulatory SBP and DBP reduction induced by addition of valsartan or losartan to amlodipine in the randomized patients who completed the study (n = 166).
Figure 2
Figure 2
Twenty-four-hour SBP and DBP after treatment with monotherapy (4 weeks) and after losartan or valsartan added to amlodipine (8 weeks) in the randomized patients who completed the study (n = 166).
Figure 3
Figure 3
Mean differences from monotherapy in hourly SBP and DBP values after 4 weeks of losartan or valsartan added to amlodipine in the randomized patients who completed the study (n = 166).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC 7 Report. JAMA. 2003;289:2560–2572. - PubMed
    1. European Society of Hypertension-European Society of Cardiology Guidelines Committee 2003 European Society of Hypertension/European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011–1053. - PubMed
    1. Turnbull E. Effects of different blood-pressure lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527–1535. - PubMed
    1. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until March 1, 2003. J Hypertens. 2003;21:1055–1076. - PubMed
    1. Hansson L, Zanchetti A, Carruthers SG, et al. for the HOT study group Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet. 1998;351:1755–1762. - PubMed

Publication types

MeSH terms